Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opaganib in hospitalized adults with severe COVID-19 pneumonia
MOH_2020-09-06_009160Phase 3Completed
- Sponsor
- RedHill Biopharma
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and pneumonia comparing Standard of care + opaganib with Standard of care + placebo (2 arms). Primary endpoint: Proportion of patients requiring intubation and mechanical ventilation by Day 14. Started Aug 2020; status: completed.
02
Drugs
Opaganib
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on MOH_2020-09-06_009160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-06_009160.